Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions to Lower Hyperhomocyst(e)inaemia

Author： Nallamothu B.K.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.20, Iss.7, 2002-01, pp. : 429-442

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is Hyperhomocyst(e)inemia A Humoral Predictor of Coronary Heart Disease?

By  

Current Pharmaceutical Design, Vol. 11, Iss. 17, 2005-07 ,pp. : 2187-2197

Bentham Science Publishers

Access to resources Recommend Favorite

Patients With Atherosclerotic Vascular Disease: How Low Should Plasma Homocyst(e)ine Levels Go?

By Spence J.D.  

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 2, 2001-01 ,pp. : 85-89

Adis International

Access to resources Recommend Favorite

Asymmetric Dimethyl-L-Arginine (ADMA): A Possible Link Between Homocyst(e)ine and Endothelial Dysfunction

By  

Current Drug Metabolism, Vol. 6, Iss. 1, 2005-02 ,pp. : 3-14

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

By Nieminen Tuomo   Käähöönen Mika   Viiri Leena E   Gröönroos Paula   Lehtimääki Terho  

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1475-1486

Future Medicine

Access to resources Recommend Favorite

Pravastatin: A Pharmacoeconomic Review of its use in Primary and Secondary Prevention of Coronary Heart Disease

By Coukell A.J.   Wilde M.I.  

PharmacoEconomics, Vol. 14, Iss. 2, 1998-08 ,pp. : 217-236

Adis International

Access to resources Recommend Favorite